Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related acute myeloid leukemia.

Official Title

Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Keywords

Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related AML, AML with MDS related changes, Leukemia, Myeloid Leukemia, Leukemia, Myeloid, Acute, Cytarabine, Daunorubicin, Glasdegib, CPX-351, CPX-351 and Glasdegib

Eligibility

Locations

  • UCSF
    San Francisco California 94143 United States
  • University of California, Davis
    Sacramento California 95817 United States
  • University of California, Los Angeles
    Los Angeles California 90095 United States
  • Chao Family Comprehensive Cancer Center, University of California, Irvine
    Orange California 92868 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT04231851
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated